The potential prevention and early detection results of in vitro diagnostics include reduced treatments and higher survival rates.
In vitro diagnostics (IVD) are a prominent and fast-emerging segment of the global healthcare sector. IVD tests analyze human samples such as blood, urine, or tissue and provide information for making healthcare decisions. Key IVD tests include pregnancy test kits, blood glucose tests, laboratory tests for infectious disease, regular blood tests for cholesterol and hemoglobin content, genetic tests for various genetic diseases, etc.
Interest in companion diagnostics is also growing as providers and patients embrace the idea of selecting the best therapy for a particular patient based on their disease-related gene sequence.
IVDs have potential in prevention and early detection resulting in reduced treatment, enhanced therapy success, higher survival rates, and improved quality of life.
An IQ4I Research & Consultancy analysis has found that the global IVD market is expected to grow at mid-single digit CAGR to reach $88.00 billion by 2020. The IVD market is largely driven by increased incidence of chronic and infectious disease, demand for point-of-care testing (POCT) devices, technological advancement, personalized medicine, cost-effectiveness, and healthcare awareness. On the flip side, intensified competition, reimbursement issues, and affordability of healthcare diagnostics are hampering IVD market growth.
Based on techniques used in IVD, the market is segmented into clinical chemistry, immunology, hematology, coagulation, microbiology, molecular diagnostics, and other clinical instruments. The immunology segment had the largest revenue in 2013 and is poised to reach $35.3 billion by 2020. The molecular diagnostics market segment is expected to grow at the highest CAGR (more than 8%) during the forecast period. Among various IVD products, reagents commanded the largest market in 2013, followed by the instruments segment.
The infectious disease segment is the largest part of the market, and continued growth is expected. The oncology segment is expected to grow at the highest CAGR (more than 7%) during the forecast period. Among the various end-users of IVDs, the hospital segment accounted for the largest market in 2013 and is expected to reach half of the market size by 2020.
Developed regions such as North America commanded the largest market in 2013 and are expected to reach $38.19 billion by 2020. Significant investments in healthcare infrastructures and availability of government funds improved market growth in this region. However, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period due to increased healthcare awareness, improved economic growth, and increasing disposable incomes. Significant mergers and acquisitions, collaborations, and joint ventures are the industry trends that are playing a major role for the market growth.
Major players in the IVD market include Roche Diagnostics, Bio-Rad Laboratories, Becton, Dickinson, Bayer, Sysmex, Alere, Abbott Laboratories, Siemens Healthcare, Johnson & Johnson, Danaher, and Biomerieux.
Satish Birudukota ([email protected]) is associate director & head, market research, IQ4I Research & Consultancy.
This article was originally published in the September 24 issue of Clinical OMICs. For more content like this and details on how to get a free subscription to this digital publication, go to www.clinicalomics.com.